[go: up one dir, main page]

CL2008002025A1 - Solución farmacéutica oral que comprende telbivudina, sacarina de sodio, un sabor soluble, ácido benzoico y un buffer citrato, útil para el tratamiento de la hepatitis b en población pediátrica, en personas con dificultades para tragar y en sujetos renalmente perjudicados. - Google Patents

Solución farmacéutica oral que comprende telbivudina, sacarina de sodio, un sabor soluble, ácido benzoico y un buffer citrato, útil para el tratamiento de la hepatitis b en población pediátrica, en personas con dificultades para tragar y en sujetos renalmente perjudicados.

Info

Publication number
CL2008002025A1
CL2008002025A1 CL2008002025A CL2008002025A CL2008002025A1 CL 2008002025 A1 CL2008002025 A1 CL 2008002025A1 CL 2008002025 A CL2008002025 A CL 2008002025A CL 2008002025 A CL2008002025 A CL 2008002025A CL 2008002025 A1 CL2008002025 A1 CL 2008002025A1
Authority
CL
Chile
Prior art keywords
telbivudine
hepatitis
people
treatment
useful
Prior art date
Application number
CL2008002025A
Other languages
English (en)
Inventor
Nabila Sekkat
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38724394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002025(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2008002025A1 publication Critical patent/CL2008002025A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Soluciones farmacéuticas orales que comprenden telbivudina destinadas al tratamiento de la hepatitis B en la población pediátrica, en personas con dificultades para tragar y en sujetos renalmente perjudicados.
CL2008002025A 2007-07-12 2008-07-11 Solución farmacéutica oral que comprende telbivudina, sacarina de sodio, un sabor soluble, ácido benzoico y un buffer citrato, útil para el tratamiento de la hepatitis b en población pediátrica, en personas con dificultades para tragar y en sujetos renalmente perjudicados. CL2008002025A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07112381 2007-07-12

Publications (1)

Publication Number Publication Date
CL2008002025A1 true CL2008002025A1 (es) 2009-05-08

Family

ID=38724394

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002025A CL2008002025A1 (es) 2007-07-12 2008-07-11 Solución farmacéutica oral que comprende telbivudina, sacarina de sodio, un sabor soluble, ácido benzoico y un buffer citrato, útil para el tratamiento de la hepatitis b en población pediátrica, en personas con dificultades para tragar y en sujetos renalmente perjudicados.

Country Status (22)

Country Link
US (1) US8445457B2 (es)
EP (1) EP2178503A1 (es)
JP (1) JP5314014B2 (es)
KR (3) KR20140019040A (es)
CN (1) CN101686938B (es)
AR (1) AR067630A1 (es)
AU (1) AU2008274170B2 (es)
BR (1) BRPI0815562A2 (es)
CA (1) CA2693609A1 (es)
CL (1) CL2008002025A1 (es)
CO (1) CO6270204A2 (es)
EC (1) ECSP109871A (es)
IL (1) IL202961A (es)
MA (1) MA31507B1 (es)
MY (1) MY147366A (es)
NZ (1) NZ582443A (es)
PE (2) PE20090476A1 (es)
RU (1) RU2493826C2 (es)
TN (1) TN2010000008A1 (es)
TW (1) TW200911302A (es)
WO (1) WO2009007426A1 (es)
ZA (1) ZA200908993B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2712358T1 (sl) 2011-05-13 2017-03-31 Array Biopharma, Inc. Spojine pirolidinil sečnine, pirolidinil tiosečnine in pirolidinil gvanidina kot inhibitorji kinaze trka
WO2014059363A1 (en) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals Llc Oral solution formulations of aripiprazole
PT3154959T (pt) 2014-05-15 2019-09-24 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoxietil)-pirrolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)ureia como inibidor da cinase trka
EP3288562B1 (en) * 2015-04-26 2022-03-16 MacKay Memorial Hospital Method for improving kidney and/or heart function in patients with kidney disease
CN107550866A (zh) * 2016-06-30 2018-01-09 康普药业股份有限公司 一种替比夫定制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856364A (en) 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
WO1999016447A1 (fr) 1997-09-26 1999-04-08 Wakamoto Pharmaceutical Co., Ltd. Preparation aqueuse contenant un agent antiviral a ossature purine ou pyrimidine
DE19817264A1 (de) 1998-04-18 1999-10-21 Bayer Ag Neue Dihydropyrimidine
DE19817265A1 (de) 1998-04-18 1999-10-21 Bayer Ag Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe
AR037131A1 (es) 2001-10-31 2004-10-20 Schering Corp Formulaciones de jarabe de ribavirina
TWI244393B (en) * 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
WO2006130217A2 (en) 2005-04-01 2006-12-07 The Regents Of The University Of California Substituted phosphate esters of nucleoside phosphonates

Also Published As

Publication number Publication date
CO6270204A2 (es) 2011-04-20
US20100197629A1 (en) 2010-08-05
ZA200908993B (en) 2010-09-29
WO2009007426A1 (en) 2009-01-15
BRPI0815562A2 (pt) 2015-02-18
ECSP109871A (es) 2010-02-26
AU2008274170A1 (en) 2009-01-15
MA31507B1 (fr) 2010-07-01
CN101686938B (zh) 2012-09-05
CN101686938A (zh) 2010-03-31
TN2010000008A1 (en) 2011-09-26
PE20130180A1 (es) 2013-03-06
KR20120078754A (ko) 2012-07-10
NZ582443A (en) 2011-04-29
KR20140019040A (ko) 2014-02-13
IL202961A (en) 2013-10-31
JP5314014B2 (ja) 2013-10-16
EP2178503A1 (en) 2010-04-28
JP2010533146A (ja) 2010-10-21
RU2493826C2 (ru) 2013-09-27
KR20100029829A (ko) 2010-03-17
AR067630A1 (es) 2009-10-21
RU2010104395A (ru) 2011-08-20
US8445457B2 (en) 2013-05-21
PE20090476A1 (es) 2009-05-12
AU2008274170B2 (en) 2011-06-09
TW200911302A (en) 2009-03-16
MY147366A (en) 2012-11-30
CA2693609A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
FI3457135T3 (fi) Fabryn taudin hoitovaihtoehtoja
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
FR2878159B1 (fr) Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
NO20043998L (no) Oral administreringsform for tungtloselige basiske aktive virkestoffer
NO20076613L (no) Farmasoytiske formuleringer og anvendelse derav
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
ZA200800239B (en) Mucosal or enteral administration of biobogically active macromolecules
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
CO6280475A2 (es) Metodo para tratar la deficiencia de vitamina b12
DOP2012000050A (es) Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina
CL2008002025A1 (es) Solución farmacéutica oral que comprende telbivudina, sacarina de sodio, un sabor soluble, ácido benzoico y un buffer citrato, útil para el tratamiento de la hepatitis b en población pediátrica, en personas con dificultades para tragar y en sujetos renalmente perjudicados.
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
PE20060588A1 (es) Composiciones farmaceuticas que contienen flibanserina
NO20034863D0 (no) Deuterert 3-piperidinopropiofenon og medikamenter inneholdende disse
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
AR061668A1 (es) Jarabes antihistaminicos, estables al almacenamiento, sin azucar
CY1116831T1 (el) ΧΡΗΣΗ 24-norUDCA
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
ATE474561T1 (de) Orodispersible pharmazeutische zusammensetzung für die orale, oromukosale oder sublinguale verabreichung von agomelatin
DK1401405T3 (da) Orale, farmaceutiske sammensætninger med forbedret biotilgængelighed
UA90893C2 (ru) Пероральная дозированная форма производных гемцитабина
DK1560575T3 (da) 3,5,3'-triiodthyroninsulfat som thyromimetisk middel og farmaceutiske formuleringer deraf
AR023815A1 (es) Solucion oral de prucalopride
ATE549016T1 (de) Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe
PA8800601A1 (es) Productos quimioterapeuticos cristalinos